Background. Overwhelming post-splenectomy infection (OPSI) is a serious complication of asplenia. Clinical guidelines recommend numerous measures to reduce the risk of OPSI, but awareness and adherence to preventative measures are generally poor. We aimed to determine whether a registry for asplenic/hyposplenic patients was associated with a reduction in the incidence of infection with encapsulated bacteria.
Overwhelming post-splenectomy infection (OPSI) is a serious complication of asplenia/hyposplenism, associated with significant morbidity and mortality [1] . Patients are at particular risk of infection with encapsulated organisms, including Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis. Clinical guidelines recommend a number of measures to reduce the risk of OPSI, including education about infection risk and prevention, vaccination, antibiotic prophylaxis, and an emergency action plan.
However, awareness and adherence to preventative measures have generally been found to be poor [2] . In an attempt to address this, Spleen Australia (formerly the Victorian Spleen Registry [VSR] ) was established in 2003 [3] . Spleen Australia enrolls patients with asplenia/hyposplenism in several Australian jurisdictions and aims to increase the awareness of post-splenectomy infection in patients with asplenia/hyposplenism by education of patients and their healthcare providers and by dissemination of up-to-date recommendations to prevent infection [4] . In this study, we aimed to define the incidence of infection with S. pneumoniae, N. meningitidis, and H. influenzae type b in asplenic patients before and after registration with Spleen Australia in order to determine whether the incidence of infection decreased following registration.
METHODS

Study Population
All patients with a clinical diagnosis of asplenia or hyposplenia in the states of Victoria, Queensland, and Tasmania are eligible for enrollment in Spleen Australia. The majority of patients are resident in Victoria where the registry was first established; enrollment of patients in other jurisdictions commenced more recently. Patients are identified either retrospectively (if they have a history of prior splenectomy) or prospectively (from hospital-based surveillance). On enrollment, patients are contacted by phone, and an education kit is sent with a personalized vaccine report. The education kit includes a patient information sheet, alert cards (carried by the patient to make healthcare workers aware of their history of splenectomy), immunization record card, an educational DVD, the current newsletter, and a refrigerator magnet (with an action plan in case of illness). Infection prevention measures recommended to patients include general education including awareness and risk of infection, immunization recommendations, antibiotic prophylaxis for at least 3 years following splenectomy, and an emergency plan [3] . Details of the reason for the splenectomy and vaccinations that have been administered are confirmed with the hospital, general practitioner, and/or patient. Reminders are sent to general practitioners and patients in an annual newsletter that details any changes to vaccination recommendations and recommendations for an annual influenza vaccination [3] . Current recommendations were recently published in national guidelines and are available at the Spleen Australia website [4] .
Data Linkage
We linked data from Spleen Australia/VSR with the Public Health Events Surveillance System maintained by the Victorian Government Department of Health and Human Services (DHHS) for the period 1 January 2000 (the date from which DHHS notification data were available) to 22 April 2014. In Victoria, the Public Health and Wellbeing Act 2008 requires medical practitioners and laboratories to notify DHHS of cases of invasive pneumococcal disease (IPD), invasive meningococcal disease (IMD), and Hib. Patients who were resident outside the state of Victoria and those who had infection prior to splenectomy were excluded from the study. A deterministic linkage was performed using the patient's name and date of birth.
Statistical Analyses
Poisson regression was used to estimate the relative hazard of OPSI. The preregistration risk period was defined as commencing on either the date of splenectomy or 1 January 2000 (whichever was later). For patients with medical hyposplenia, the date of "splenectomy" was the date of diagnosis of hyposplenia. The post-registration risk period was defined as commencing on the date of registration to the earlier of the date of death or 22 April 2014. In this model, the dependent variable was the number of OPSIs, and the log of duration of risk was included in the model as an offset, with the coefficient constrained to 1. This analysis accounted for repeated risk periods in the same patients. Robust standard errors were estimated using the Huber-White sandwich estimator. Analyses were performed using Stata, version 14.1 for Windows (College Station, Texas).
This project was conducted by analyzing previously collected clinical information. Registrants provided written informed consent for their data to be collected upon registration with Spleen Australia. Ethical permission to review these data was granted by the Human Research Ethics Committee at Alfred Health and Monash University (project 108/14), and permission to access notifiable diseases data was granted by the Victorian DHHS.
RESULTS
Characteristics of Cohort
There were 3275 registrants with Spleen Australia in April 2014. Of these, 47 were excluded from further analysis as they were resident interstate, and 7 were excluded because the notifiable disease occurred prior to splenectomy. Of the remaining 3221 Victorian participants, the median age at splenectomy was 38 years (interquartile range [IQR], 21-58 years) and the age of registrants in April 2014 was 59 years (IQR, 49-70 years). Registration occurred at a median of 2.3 years (IQR, 1 month, 23 years) after splenectomy, with 48% registering within 1 year of splenectomy. The most common reasons for splenectomy were trauma (31%), nonmalignant hematological disorders (23%), and incidental reasons (10%; Table 1 ).
Characteristics of Notifiable Infections
Among Spleen Australia registrants, there were 28 notifications, including 27 of S. pneumoniae and 1 of N. meningitidis serogroup W. No cases of Hib were reported. Of these infections, 1 case occurred within 6 months of splenectomy, 3 cases occurred between 6 months and 3 years of splenectomy, 4 occurred within 3 and 10 years of splenectomy, and 20 occurred more than 10 years after splenectomy. Two infections with S. pneumoniae were fatal. Registrants splenectomized due to hyposplenia experienced the highest cumulative incidence of infections (n = 2 infections; 1.9%; Table 1), followed by individuals splenectomized due to nonmalignant hematological disease (n = 10 infections; 1.3%; Table 1 ). No infections occurred among registrants splenectomized due to cancer.
Of the 27 cases of IPD infection was caused by serotypes included in the 7-valent conjugate vaccine in 5 cases (23F n = 2, 14, 18C, 19F), serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13) in 13 cases (as above, as well as 6C n = 5, 19A, 6A, 7F), and serotypes included in the 23-valent polysaccharide vaccine in 19 cases (as above, as well as 22F n = 5, 33F) and nonvaccine serotypes in 8 cases (23A n = 3, 23B n = 2, 35F, 38, nontypeable; Figure 1 ).
Incidence of Notifiable Infections
There were 24 infections in 16 026 patient-years at risk prior to registration (incidence 150 per 100 000 patient-years). There were 4 infections in 11 110 patient-years following registration (incidence 36 per 100 000 patient-years). Of these 4 infections, 1 occurred between 6 and 12 months after registration, 2 occurred between 1 and 2 years after registration, and 1 occurred at 3.6 years after registration. Registration with Spleen Australia was associated with a 69% reduction in the risk of infection (incidence rate ratio, 0.31; 95% CI, 0.12; 0.83, P = .019).
DISCUSSION
To our knowledge, the results of this study are the first to demonstrate that a registry for people with asplenia/hyposplenism can significantly reduce the incidence of infection with encapsulated bacteria. We are not aware of similar studies of patient registries for this patient group. Based on the absolute reduction in incidence, we estimate that Spleen Australia prevents around 5-6 invasive infections with encapsulated organisms per year in the 6000 patients currently registered.
Infection with encapsulated organisms is uncommon but occurs at a higher rate in patients with asplenia/hyposplenism.
The incidence of infections documented in this study is of a similar magnitude to the incidence of OPSIs reported in the literature (70-300 infections per 100 000 patient-years) and is much higher than the estimated overall incidence of IPD in Victoria (8-11 infections per 100 000 patient-years) [5, 6] .
We found that most infections in this study were due to S. pneumoniae, reinforcing the importance of pneumococcal vaccination in this high-risk group. It is likely that the change in distribution of IPD serotypes reflects both the direct protective effects of vaccination and herd immunity as a result of progressive inclusion of IPD vaccines providing broad coverage against predominant serotypes on the national childhood immunization schedule. The polysaccharide vaccine has been funded for elderly Australians (aged >65 years) and Indigenous Australians (aged >50 years) since 1999; the 7-valent conjugate vaccine was introduced into the childhood schedule in 2005 and the 13-valent conjugate vaccine was introduced in 2011. However, pneumococcal vaccines for high-risk individuals outside this group are not funded under the national immunization program. Data from IPD surveillance in Australia demonstrate smaller declines in IPD in adults attributed to indirect protection (20% and 35% in those aged 50-64 years and >65 year, respectively), with no significant change in estimated polysaccharide vaccine coverage [7] . Only 2 cases of IPD due to PCV7 serotypes in this study were reported following the introduction of PCV7 into the childhood program in 2005, and no cases of IPD due to PCV13 serotypes were reported following the introduction of PCV13 in 2011. Only 1 preregistration case of IMD was reported in this study, reflecting the much lower population incidence of meningococcal infection in Australia [8] . The single case of IMD involved serogroup W, which was then unusual but has become increasingly common in recent years [9] . The lack of cases of Hib likely reflects the substantial herd immunity effect since the introduction of the national (Hib) vaccination program in 1993 [10] .
Four registrants developed IPD following registration. Median time between registration and infection was 2.4 years, hence the 4 post-registration infections likely reflect true incidence among this population and not ascertainment bias resulting from increased awareness and potentially more intensive investigation immediately following registration. Three cases were due to infection with nonvaccine serotypes, highlighting the need for continued vigilance and adherence to infection prevention guidelines. It is important that the serotypes of nonvaccine strain infections be monitored as vaccine-induced serotype replacement has been observed elsewhere [11] . Only 1 registrant was infected with a vaccine serotype post-splenectomy (serotype 14), which is included in both the PCV7 and PCV13 vaccines. This registrant suffered from chronic lymphoblastic leukemia, which proved ultimately fatal. Infection with IPD serotype 14 occurred in 2011, 1 year prior to death and despite receiving the PCV13 in 2010. This registrant was immunosuppressed and thus at even greater risk of infection.
Previous studies of patients with asplenia/hyposplenia have reported that adherence to infection prevention measures in this group is poor [12] [13] [14] [15] [16] . Spleen Australia functions by actively providing patient and physician education and by disseminating up-to-date recommendations on vaccine and other preventive measures, which in turn reduces the incidence of severe infections [3] . However, in order to effectively reduce the incidence of severe infection among registrants, the registry relies on compliance of registrants and physicians with advice and infection prevention guidelines. To assess adherence to infection prevention guidelines, a cross-sectional survey was administered to registrants in 2010, which demonstrated that adherence to guidelines among Spleen Australia registrants was higher than reported elsewhere [3] . While respondents were less likely to maintain an emergency supply of antibiotics as time increased since splenectomy, the proportion of Spleen Australia registrants who reported doing so remained high at 72.3% for individuals aged <12 months and 61.3% for those aged >12 months post-splenectomy. In comparison, previous studies have reported that only 7% to 11% of asplenic patients maintained an emergency supply of antibiotics [17, 18] . The majority of registrants also reported receiving the recommended vaccinations and boosters [3] . Ongoing dissemination of up-todate infection prevention information, increased awareness of post-splenectomy infection, and active registrant follow-up are likely reasons why compliance with infection prevention measures was found to be higher among Spleen Australia registrants than reported elsewhere.
The strengths of this study are the paired nature of the analysis, which implicitly accounts for patient-specific factors and reduces the potential for "healthy user" bias, which is inherent in other vaccination studies, and high adherence to infection control guidelines by registrants. There have not been any major changes in the case definition for these infections over this time, and the use of more sensitive nucleic acid testing for pneumococci remains uncommon in Australia. Thus, we would expect that ascertainment would be similar during the study period, and our results are unlikely to be biased due to changes in ascertainment over time.
Limitations included the relatively small number of patients, which precluded a more detailed analysis. We did not have data on the vaccination status of cases identified in this study, only self-reported compliance with vaccination determined from a prior survey [3] . In this survey, 79% of registrants aged >5 years since splenectomy reported having received a booster vaccine.
Infection with only 3 notifiable encapsulated bacteria was investigated in the present study. These 3 pathogens were chosen on account of the severity of the clinical outcome following invasive infection. While it has been reported that asplenic individuals may be a host for emerging infectious diseases, it does not appear that the incidence of viral respiratory tract infections or gastroenteritis is also increased among this group [19] . Hence, whether registration with Spleen Australia was also associated with a reduction in the incidence of infection with other notifiable conditions, including influenza, was not investigated.
It is likely that the baseline (preregistration) incidence of infection has been underestimated, as fatal cases may not be registered. This is likely to underestimate the protective effect of registration. While invasive S. pneumoniae, N. meningitidis, and Hib infection are notifiable, we previously found that these account for only a third of infections that require intensive care [20] . Of the remainder, a third did not have a microbiological diagnosis (reflecting the imperfect sensitivity of diagnostic tests) and a third had infections with other organisms. Additionally, a previous study has found that cases of infection that required admission but not intensive care were much more common [20] ; these may also include noninvasive infections with vaccine-preventable encapsulated organisms such as pneumococcal pneumonia. In that study, we reported that the incidence of infection requiring intensive care unit admission was lower after registration than prior to registration, but this result was potentially biased by case ascertainment [20] As the earliest registrant splenectomy was performed in 1936 and linked notification data were only available from 2000, it is possible that registrants experienced IPD, IMD, or Hib infections prior to 2000 that were not included in this analysis. However, as 61% (n = 1924) of all Spleen Australia registrant splenectomies were performed between 2000 and 2014, the majority of registrants were splenectomized within the study period, ensuring that all post-splenectomy infections for the majority of patients were included in this study.
We are uncertain as to the proportion of Victorian patients with asplenia/hyposplenism who are registered with Spleen Australia. A Victorian study estimated around 300 splenectomies per year over the period 1998-2006 [21] , but the incidence of splenectomy is becoming less common with the increasing use of splenic embolization for traumatic injury. Currently, Spleen Australia registers around 250 Victorian patients per year who have had recent splenectomies and a similar number with a more remote history of splenectomy (unpublished data). More recently, funding has become available to register patients in Tasmania and Queensland, with plans to expand to other Australian jurisdictions in the future. While we have not attempted a formal cost effectiveness analysis, we note that the registry currently has 1.5 equivalent full-time nursing staff.
Infections due to vaccine-preventable, encapsulated bacteria, particularly S. pneumoniae, occur at a higher incidence in patients with asplenia/hyposplenism than in the general population. We have previously shown good adherence to measures to prevent infection in registrants. A patient registry for patients with asplenia/ hyposplenism that provides education, clinical advice, and health promotion reminders was associated with a significant reduction in the risk of infection with encapsulated bacteria. Clinicians caring for patients with asplenia/hyposplenism should consider establishing a patient registry to reduce the risk of infection. 
